| Business Summary | | Feminique
Corporation's
business
operations
in
1999
were
principally
conducted
through
one
wholly
owned
subsidiary,
Quality
Health
Products,
Inc.,
a
company
organized
to
market
the
line
of
Feminine
Hygiene
Products.
In
addition,
the
Company
holds
the
license
rights
to
Mitolactol,
a
cytotoxic
chemotherapy
agent
that
holds
Orphan
Drug
Status
for
both
the
treatment
of
cervical
cancer
and
brain
cancer.
The
feminine
hygiene
branded
products
operation
constitutes
the
Company's
core
business.
Subsequently,
the
Company
became
a
distributor
of
consumer
feminine
hygiene
and
family
planning
products
which
are
sold
nationwide
to
major
chain
stores,
distributors
and
wholesalers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Feminique
Corporation
is
a
distributor
of
consumer
feminine
hygiene
and
family
planning
products
which
are
sold
nationwide
to
major
chain
stores,
distributors
and
wholesalers.
For
the
nine
months
ended
6/30/00,
net
sales
fell
58%
to
$696
thousand.
Net
loss
from
continuing
operations
totaled
$1.8
million,
up
from
$191
thousand.
Revenues
reflect
the
restructuring
of
the
Company.
Higher
loss
reflects
the
inclusion
of
a
$1
million
charge
for
an
intangible
asset
write
off. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Jonathan Rosen, 37 Pres,
CEO | $226K | John Grein, 53 Sec.
and Sr. VP of Fin. | 47K | Dollar amounts are as of 30-Sep-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|